<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521049</url>
  </required_header>
  <id_info>
    <org_study_id>tubular markers</org_study_id>
    <nct_id>NCT04521049</nct_id>
  </id_info>
  <brief_title>Tubular Markers in Response to Saxagliptin Therapy</brief_title>
  <official_title>A New Clinical Utility for Tubular Markers to Identify Kidney Responders to Saxagliptin Treatment in Patients With Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      the study aims to investigate whether treatment with saxagliptin would induce beneficial&#xD;
      changes in renal NGAL and L-FABP biomarkers and if they would be used as a tool to identify&#xD;
      patients' categories with a particular renal response to DPP-4inhibition. Secondly, to find&#xD;
      an association between NGAL and L-FABP, and the relevant renal parameters for both baseline&#xD;
      values and rate of changes across defined time points.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic kidney disease (DKD) is considered a substantial cause of end-stage kidney disease&#xD;
      (ESKD) worldwide. Incorporation of renoprotective options during interventions to prevent the&#xD;
      development of DKD and attenuation of its progression; is of the utmost importance.&#xD;
      Incretin-based therapies, specifically dipeptidyl peptidase 4 (DPP-4) inhibitors exhibited&#xD;
      albuminuria lowering potential beyond their antihyperglycemic effects. Saxagliptin, a potent&#xD;
      selective DPP-4 inhibitor which has been used as monotherapy or in combination with&#xD;
      antidiabetics, has demonstrated great renal efficiency on both experimental and clinical&#xD;
      scale .&#xD;
&#xD;
      Although albumin excretion rate (AER) is a powerful predictor of kidney function&#xD;
      deterioration and progressive renal dysfunction, it is primarily a marker of glomerular&#xD;
      damage and it has some drawbacks. For example; some patients may follow a non-albuminuric&#xD;
      pathway to kidney impairment, others do not progress to macroalbuminuria but remain at&#xD;
      microalbuminuria or even regress to normoalbuminuria. Thus, more sensitive and specific renal&#xD;
      biomarkers than AER will be valuable in predicting early kidney injury and the progression of&#xD;
      diabetic renal damage.&#xD;
&#xD;
      Besides glomerular damage, tubulointerstitial dysfunction largely contributes to the&#xD;
      pathology of diabetic nephropathy. Neutrophil gelatinase-associated lipocalin (NGAL) and&#xD;
      liver type fatty acid binding protein (L-FABP) are apparent as excellent biomarkers of&#xD;
      tubular damage and are earlier predictors of acute kidney injury relative to&#xD;
      microalbuminuria. NGAL is produced by neutrophils, highly expressed in tubular epithelium and&#xD;
      released from tubular cells following damage . L-FABP is expressed in the proximal tubules&#xD;
      and secreted into urine upon tubulointerstitial damage. Clinical significance of these&#xD;
      biomarkers lies in their emergence in normoalbuminuric patients and their association with&#xD;
      increased albuminuria and progression to ESRD with sustained high urinary markers' levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2019</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>to measure renal effect of saxagliptin on tubular markers</measure>
    <time_frame>3 months</time_frame>
    <description>the rate of change of uNGAL and u LFABP markers would be estimated across the two time points after saxagliptin treatment .</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to measure effect of saxagliptin on renal on albuminuria</measure>
    <time_frame>3 months</time_frame>
    <description>the rate of change of UACR would be measured across the two time points after saxagliptin treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>to classify renal responders to saxagliptin using tubular markers</measure>
    <time_frame>3 months</time_frame>
    <description>patients would be classified into high risk and low risk patients according to their marker levels</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>saxagliptin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients received 5 mg daily ( 2.5 mg daily dose was given to patients with an eGFR of &lt;50 mL/min/1.73 m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients received the antihyperglycemic medication(s) such as metformin and/or sulphonyl ureas or insulin with no added gliptins,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin 5mg</intervention_name>
    <description>Patients would be assigned to saxagliptin (Onglyza® AstraZeneca Pharmaceuticals LP, Indiana, USA), either received a dose of 5 mg or 2.5 mg daily if patients had eGFR &lt;50 mL/min/1.73 m2</description>
    <arm_group_label>saxagliptin</arm_group_label>
    <other_name>Onglyza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T2 DM,&#xD;
&#xD;
          -  prevalent albuminuria (30-3000mg/g),&#xD;
&#xD;
          -  controlled hypertension (defined as blood pressure &lt;140/90 mm Hg) on a selected&#xD;
             angiotensin receptor blocker, olmesartan 20mg/day for at least 4 weeks before&#xD;
             intervention.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  type 1 diabetes,&#xD;
&#xD;
          -  poorly controlled hypertension (140-160/90-100 mm Hg),&#xD;
&#xD;
          -  pancreatitis,&#xD;
&#xD;
          -  malignancies&#xD;
&#xD;
          -  albuminuria more than 3000mg/g.&#xD;
&#xD;
          -  cardiovascular diseases (acute myocardial infarction, cerebrovascular disease in the&#xD;
             past 6months,&#xD;
&#xD;
          -  End Stage Renal Disease (ESRD) on chronic dialysis, renal transplant, a serum&#xD;
             creatinine &gt;6.0 mg/dL, or estimated glomerular filtration rate (eGFR) &lt;30 mL/min/1.73&#xD;
             m2.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed A Elberry, prof</last_name>
    <role>Study Chair</role>
    <affiliation>Clinical Pharmacology Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Pharmacy</name>
      <address>
        <city>Al Qāhirah Al Jadīdah</city>
        <zip>0004</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://onlinelibrary.wiley.com/doi/full/10.1002/prca.201800144</url>
    <description>Urinary Proteomics as a Tool to Identify Kidney Responders to Dipeptidyl Peptidase-4 Inhibition: A Hypothesis-Generating Analysis from the MARLINA-T2D Trial</description>
  </link>
  <link>
    <url>http://www.tandfonline.com/doi/abs/10.3109/00365513.2011.645055</url>
    <description>The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP</description>
  </link>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 13, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>August 18, 2020</last_update_submitted>
  <last_update_submitted_qc>August 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Marwa Mohsen Mahmoud</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>saxagliptin</keyword>
  <keyword>uNGAL</keyword>
  <keyword>u L-FABP</keyword>
  <keyword>DKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

